HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Laurent
L
Verkoczy
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America; Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Garnett
G
Kelsoe
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America; Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Barton F
BF
Haynes
D016915:AIDS Vaccines / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology; D055808:Drug Discovery / Q000379:methods / Q000592:standards; D015483:HIV Antibodies / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015658:HIV Infections / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D009154:Mutation
D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D001323:Autoantibodies; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41